Protocol Ledger

NCT04837001 · Phase III · COMPLETED

Evaluation in STEMI Patients Using FDY-5301

Interventional Phase III clinical trial protocol NCT04837001 sponsored by Faraday Pharmaceuticals in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-02 Enrollment: 2,351 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04837001
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)2,351 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04837001
Protocol FieldVerified Registry Value
NCT IdentifierNCT04837001
Consolidated Lead SponsorFaraday Pharmaceuticals
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment2,351 participants (ACTUAL)
Registered Start Date2022-05-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04837001
Hospital Research SiteLocationSite Profile
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->
Brigham and Women's HospitalBoston, MAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI